- Ticker
- AMBU-B.CO
- Price
- 114.45
- Stock movement up
- +2.40 (2.14%)
- Company name
- Ambu A/S
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Medical Devices
- Markedsværdi
- 25.15B
- Ent værdi
- 27.91B
- Pris/omsætning
- 5.53
- Pris/bog
- 6.10
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -5.38%
- Efterfølgende P/E
- 264.75
- Fremtidig P/E
- 74.80
- PEG
- -
- EPS-vekst
- -21.64%
- 1 års afkast
- 11.39%
- 3 års afkast
- -28.87%
- 5 års afkast
- -7.93%
- 10 års afkast
- 21.61%
Senest opdateret: 2024-04-09
UDBYTTE
AMBU-B.CO betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 264.75 |
| Pris til OCF | 1006.03 |
| Pris til FCF | - |
| Pris til EBITDA | 66.19 |
| EV i forhold til EBITDA | 73.45 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 5.53 |
| Pris til egenkapital | 6.10 |
| EV i forhold til salg | 6.14 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 219.75M |
| EPS (TTM) | 0.37 |
| FCF pr. aktie (TTM) | -1.10 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 4.54B |
| Bruttofortjeneste (TTM) | 2.58B |
| Driftsindkomst (TTM) | 150.00M |
| Nettoindkomst (TTM) | 95.00M |
| EPS (TTM) | 0.37 |
| EPS (1 år frem) | 1.53 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 56.81% |
| Driftsmargin (TTM) | 3.30% |
| Fortjenstmargin (TTM) | 2.09% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 125.00M |
| Nettotilgodehavender | 709.00M |
| Omsætningsaktiver i alt | 2.21B |
| Goodwill | 1.56B |
| Immaterielle aktiver | 1.95B |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 7.01B |
| Kreditor | 509.00M |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 996.00M |
| Sum gæld | 2.88B |
| Aktionærernes egenkapital | 4.12B |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 25.00M |
| Investeringsudgifter (TTM) | 304.00M |
| Fri pengestrøm (TTM) | -279.00M |
| Udbetalt udbytte (TTM) | 15.00M |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 2.30% |
| Afkast af aktiver | 1.36% |
| Afkast af investeret kapital | 1.73% |
| Kontant afkast af investeret kapital | -5.07% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 111.65 |
| Daglig høj | 115.85 |
| Daglig lav | 111.30 |
| Daglig volumen | 733K |
| Højeste gennem alle tider | 355.40 |
| 1 års analytiker estimat | 119.40 |
| Beta | 0.55 |
| EPS (TTM) | 0.37 |
| Udbytte pr. aktie | - |
| Ex-div dato | 15 Dec 2021 |
| Næste dato for resultatpræsentation | 14 May 2024 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| AMBU-B.CO | S&P500 | |
| Nuværende prisfald fra top notering | -67.80% | -0.85% |
| Højeste prisfald | -82.62% | -56.47% |
| Højeste efterår dato | 22 Sep 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -30.90% | -11.35% |
| Gennemsnitlig tid til nyt højdepunkt | 23 days | 13 days |
| Maks. tid til nyt højdepunkt | 1367 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
25.15B
Markedsværdi kategori
Large-cap
Beskrivelse
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
Personale
4500
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Denmark
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2...
6. februar 2024
In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth wit...
30. januar 2024
For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high d...
8. november 2023
Today, Ambu announces its financial guidance for the fiscal year 2023/24. Also, today, Ambu will publish its Q4 and full-year earnings release along with its Annual Report, including the company’s Sus...
8. november 2023
Thomas Frederik Schmidt will step down as CFO of Ambu by 31 December 2023; Henrik Skak Bender named as new CFO, effective 1 January 2024. Ambu A/S has appointed Henrik Skak Bender as the company’s new...
11. oktober 2023
Today, Ambu announces its preliminary financial 2022/23 results. For the financial year 2022/23, EBIT before special items totalled DKK 302m, with an EBIT margin before special items of 6.3% (previous...
9. oktober 2023
This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as the date of Ambu’s Annual General Meeting. 2023 8 NOVEMBER 2023 An...
29. september 2023
In Q3 2022/23, Ambu delivered 8% organic revenue growth and a 7.6% EBIT margin. This was driven by Endoscopy Solutions growing 23%, due to high double-digit growth within urology and ENT, and pulmonol...
31. august 2023
Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 198,872 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2022/23 have been granted on 28 July 2023...
28. juli 2023
Ambu raises its expectations for EBIT margin before special items to 5 - 6% (previously 3 - 5%) for the full-year 2022/23, based on its preliminary Q3 results. For Q3 2022/23, EBIT before special item...
10. juli 2023
Næste side